Study of AA4500 in the Treatment of Peyronie's Disease

Phase 3

Completed

• Conditions: Peyronie's Disease
• Interventions: Biological: AA4500; Biological: Placebo

• Registration Number: NCT01221597
• Lead Sponsor: Endo Pharmaceuticals

Brief Summary

This study is a Phase 3, double-blind, randomized, placebo-controlled study of the safety and efficacy of AA4500 0.58 mg in subjects with Peyronie's disease. Approximately 400 (267 AA4500 and 133 placebo) men will be randomized. Subjects will be screened for study eligibility within 21 days before the initial injection of study drug in the first treatment cycle.

Before dosing, subjects will be stratified by degree of penile curvature deformity (ie, 30º to 60º or 61º to 90º) and then randomized into two treatment groups to receive in a 2:1 ratio either AA4500 0.58 mg or placebo.

In this study, qualified subjects may receive up to four treatment cycles; each cycle will be separated by a period of 42 days (± 5 days). During each treatment cycle, subjects will receive two injections of study drug with at least 24 hours but not more than 72 hours between injections. After the final injection of each treatment cycle, the investigator or qualified designee will model the penile plaque in an attempt to stretch or elongate the plaque. If the subject's penile curvature is reduced to \<15 degrees after the first, second, or third cycle of injections or if further treatment is not clinically indicated, subsequent treatment cycles will not be administered.

Following the maximum of four treatment cycles, each subject will be followed for additional safety and efficacy assessments on Days 169 (± 7 days), 232 (± 7 days), 295 (± 7 days), 365 (± 7 days) (nominal weeks 24, 33, 42 and 52). Subjects randomized to placebo may receive open-label AA4500 treatment after completing this study as part of another protocol.

Detailed Description

Not available

Study Timeline

• Study Start: 2010-09
• Study First Submitted: 2010-10-08
• Study First Submitted QC: 2010-10-14
• Study First Posted: 2010-10-15
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Results First Submitted: 2015-02-04
• Results First Submitted QC: 2015-03-24
• Results First Posted: 2015-04-07
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-07
• Last Update Posted: 2017-10-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 418

Inclusion Criteria

1. Be a male and be ≥ 18 years of age
2. Be in a stable relationship with a female partner/spouse for at least 3 months before screening and be willing to have vaginal intercourse with that partner/spouse
3. Have symptom(s) of Peyronie's disease for at least 12 months before the first dose of study drug and have evidence of stable disease as determined by the investigator
4. Have curvature deformity of at least 30° in the dorsal, lateral, or dorsal/lateral plane at screening. It must be possible to delineate the single plane of maximal curvature for evaluation during the study
5. Be judged to be in good health, based upon the results of a medical history, physical examination, and laboratory profile
6. Voluntarily sign and date an informed consent agreement approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC). The subject must also sign an authorization form to allow disclosure of his protected health information (PHI). The PHI authorization form and informed consent form may be an integrated form or may be separate forms depending on the institution
7. Be able to read, complete and understand the various rating instruments in English

Exclusion criteria

1. Has a penile curvature of less than 30° or greater than 90° at the screening visit

2. Has any of the following conditions:

   • Chordee in the presence or absence of hypospadias
   • Thrombosis of the dorsal penile artery and/or vein
   • Infiltration by a benign or malignant mass resulting in curvature deformity
   • Infiltration by an infectious agent, such as lymphogranuloma venereum
   • Ventral curvature from any cause
   • Presence of an active sexually transmitted disease
   • Known active hepatitis B or C
   • Known immune deficiency disease or be positive for human immunodeficiency virus (HIV)

3. Has previously undergone surgery for Peyronie's disease

4. Fails to have an erection which in the opinion of the investigator is sufficient to accurately measure the subject's penile deformity after administration of prostaglandin E1 (PGE1) or trimix

5. Has a calcified plaque as evident by appropriate radiographic evaluation, penile x-ray or penile ultrasound that would prevent proper injection of study medication. Non-contiguous stippling of calcium is acceptable for inclusion provided the calcium deposit does not interfere with the injection of AA4500 into the plaque

6. Has an isolated hourglass deformity of the penis

7. Has the plaque causing curvature of the penis located proximal to the base of the penis, so that the injection of the local anesthetic would interfere with the injection of AA4500 into the plaque

8. Has previously received alternative medical therapies for Peyronie's disease administered by the intralesional route (including, but not limited to, steroids, verapamil, and the naturally occurring low molecular weight protein, interferon-α2b) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study

9. Has received alternative medical therapies for Peyronie's disease administered by the oral (including, but not limited to, vitamin E [> 500 U], potassium aminobenzoate [Potaba], tamoxifen, colchicine, pentoxifylline, over-the-counter erectile dysfunction medications, or steroidal anti-inflammatory drugs) or topical routes (including, but not limited to, verapamil applied as a cream) within 3 months before the first dose of study drug or plans to use any of these medical therapies at any time during the study

10. Has had extracorporeal shock wave therapy (ESWT) for correction of Peyronie's disease within the 6-month period before screening or plans to have ESWT at any time during the study

11. Has used any mechanical type device for correction of Peyronie's disease within the 2-week period before screening or plans to use any these devices at any time during the study

12. Has used a mechanical device to induce a passive erection within the 2-week period before screening or plans to use any of these devices at any time during the study

13. Has significant erectile dysfunction that has failed to respond to oral treatment with phosphodiesterase type 5 (PDE5) inhibitors

14. Has a penile Duplex Doppler ultrasound evaluation at screening that shows compromised penile hemodynamics that in the opinion of the investigator is clinically significant

15. Has uncontrolled hypertension, as determined by the investigator

16. Has a known recent history of stroke, bleeding, or other significant medical condition, which in the investigator's opinion would make the subject unsuitable for enrollment in the study

17. Is unwilling or unable to cooperate with the requirements of the study including completion of all scheduled study visits

18. Has received an investigational drug or treatment within 30 days before the first dose of study drug

19. Has a known systemic allergy to collagenase or any other excipient of AA4500

20. Has a known allergy to any concomitant medication required as per the protocol

21. Has received anticoagulant medication (except for ≤ 165 mg aspirin daily or ≤ 800 mg of over-the-counter non-steroidal anti-inflammatory drugs [NSAIDS] daily) during the 7 days before each dose of study drug

22. Has received any collagenase treatments within 30 days of the first dose of study drug

23. Has, at any time, received AA4500 for the treatment of Peyronie's disease

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AA4500	AA4500	collagenase clostridium histolyticum
Placebo	Placebo	placebo

Primary Outcome Measures

Name	Time	Method
Change From Baseline in the Peyronie's Disease Bother Domain of the Peyronie's Disease Questionnaire (PDQ)	Baseline and Week 52	Peyronie's disease bother score range 0 (no issue or not at all bothered) to 4 (extremely bothered) on 4 questions; total score range 0 to 16. A decrease in the change from baseline total score in the Peyronie's disease bother domain of the PDQ is indicated by a negative number.
Percentage Change From Baseline in Penile Curvature	Baseline and Week 52	A negative value in the percentage change from baseline in penile curvature deformity (angle measured in degrees) indicates less curvature.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline in Penile Length	Baseline and Week 52	A negative value represents a reduction in measurement from baseline.
Change From Baseline in the Penile Pain Domain of the PDQ in Subjects With Baseline Penile Pain Score ≥4	Baseline and Week 52	Penile pain scale range 0 (no pain) to 10 (extreme pain) on 3 questions; total score range 0 to 30. A decrease in the change from baseline total score in the penile pain domain of the PDQ is indicated by a negative number. Subjects were required to have a penile pain score of 4 or greater at baseline.
A Responder Analysis Based on Subject Overall Global Assessment of Peyronie's Disease	Week 52	A responder was defined as a subject who recorded his Peyronie's disease had either improved in a small but important way, moderately improved, or much improved in overall global assessment question.
Change in the Overall Satisfaction Domain of the International Index of Erectile Function (IIEF)	Baseline and Week 52	Overall satisfaction domain of the IIEF score range 0 to 5 on 2 questions where higher scores indicate improved function or satisfaction; total score range 0 to 10.
Composite Responder Based on Change in Curvature Deformity and Change in Peyronie's Disease Bother Score	Week 52	A responder was defined as a subject who satisfied the following 2 criteria at that visit: a) percent reduction from baseline in curvature deformity was ≥20% and b) reduction from baseline in PDQ Peyronie's disease bother score was ≥1, or had a change from reporting no sexual activity at screening to reporting sexual activity.
Change From Baseline in the Severity of Peyronie's Disease Physical and Psychological Symptoms	Baseline and Week 52	Peyronie's disease symptoms (physical and psychological) severity score range 0 (none) to 4 (very severe) on 6 questions; total score range 0 to 24. A decrease in the change from baseline total score in the Peyronie's disease symptoms domain of the PDQ is indicated by a negative number.
Change From Baseline in Penile Plaque Consistency	Baseline and Week 52	Penile plaque consistency score range 1 (non-palpable) to 5 (hard). A decrease in the change from baseline score in penile plaque consistency is indicated by a negative number.

Trial Locations

Locations (34)

Tristate Urologic Services PSC Inc. dba TUG Research; 🇺🇸 Cincinnati, Ohio, United States

Baylor College of Medicine, Department of Urology; 🇺🇸 Houston, Texas, United States

Urology Associates Medical Group; 🇺🇸 Burbank, California, United States

California Professional Research; 🇺🇸 Newport Beach, California, United States

San Diego Sexual Medicine; 🇺🇸 San Diego, California, United States

Grove Hill Clinical Research, Grove Hill Medical Center; 🇺🇸 New Britain, Connecticut, United States

Southeastern Medical Research Institute; 🇺🇸 Columbus, Georgia, United States

DuPage Medical Group; 🇺🇸 Downers Grove, Illinois, United States

Urology of Indiana LLC; 🇺🇸 Avon, Indiana, United States

Chesapeake Urology Research Associates; 🇺🇸 Baltimore, Maryland, United States

Mayo Clinic at Rochester, Dept. of Urology; 🇺🇸 Rochester, Minnesota, United States

Center for Reproductive Medicine; 🇺🇸 Hackensack, New Jersey, United States

Wake Urological Associates; 🇺🇸 Raleigh, North Carolina, United States

Alliance Urology Specialists, PA; 🇺🇸 Greensboro, North Carolina, United States

Urology Health Specialists,LLC; 🇺🇸 Bryn Mawr, Pennsylvania, United States

Alpha Clinical Research, LLC; 🇺🇸 Clarksville, Tennessee, United States

Urology Associates of North Texas; 🇺🇸 Arlington, Texas, United States

Urology of Virginia - Sentara Medical Group; 🇺🇸 Norfolk, Virginia, United States

Medical College of Wisconsin, Department of Urology; 🇺🇸 Milwaukee, Wisconsin, United States

Australian Centre for Sexual Health; 🇦🇺 St. Leonards, New South Wales, Australia

Western Urology; 🇦🇺 Westmead, New South Wales, Australia

AusTrials; 🇦🇺 Kipparing, Queensland, Australia

The Urology Center, PC; 🇺🇸 New Haven, Connecticut, United States

Johns Hopkins Hospital; 🇺🇸 Baltimore, Maryland, United States

Mens Health Boston; 🇺🇸 Brookline, Massachusetts, United States

Palm Beach Urology Associates; 🇺🇸 Wellington, Florida, United States

HOPE Research Institute, LLC; 🇺🇸 Phoenix, Arizona, United States

DCT-Celebration, LLC dba Discovery Clinical Trials; 🇺🇸 Celebration, Florida, United States

Salt Lake Research, PLLC; 🇺🇸 Salt Lake City, Utah, United States

Repatriation General Hospital; 🇦🇺 Daws Park, South Australia, Australia

Australian Urology Associates Pty Ltd; 🇦🇺 Malvern, Victoria, Australia

Urology Centers of Alabama, PC; 🇺🇸 Homewood, Alabama, United States

Urological Associates of Lancaster; 🇺🇸 Lancaster, Pennsylvania, United States

Division of Urology at Maimonides Medical Center; 🇺🇸 Brooklyn, New York, United States